Veopoz® (pozelimab-bbfg)

Veopoz is covered only for the FDA‑approved treatment of CHAPLE (CD55‑deficient protein‑losing enteropathy) in patients ≥1 year with genetic confirmation of biallelic CD55 loss‑of‑function mutation; patients without that confirmation, <1 year old, without recent active disease, with prior meningococcal infection, or not appropriately vaccinated are excluded. Coverage requires documentation of serum albumin ≤3.2 g/dL and active signs/symptoms within 6 months, compliance with ACIP meningococcal/pneumococcal/Hib vaccinations, prescribing by a CHAPLE‑experienced physician, initial approval for 3 months (renewal 12 months) with specified dosing (30 mg/kg IV Day 1, then 10 mg/kg SC weekly from Day 8, up‑titration to 12 mg/kg if needed, max 800 mg weekly) and documented clinical response for reauthorization.

"Reauthorization requires that the patient "Has experienced a response to therapy."